The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.
Jenna Payesko
Advertisement
Articles by Jenna Payesko
The FDA has accepted a biologics license application for galcanezumab as a prophylactic treatment for migraines.
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
3
This Week on NeurologyLive® — September 15, 2025
4
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
5
